Research Article - (2011) Volume 2, Issue 3
Adoptive Immunotherapy Against Malignant Glioma Using Survivin-specific CTLs Expanded by W6/32 Antibody-mediated Artificial Antigen-presenting Cells
- Xiaoling Lu1,2,3*, Jiaqi Shi4, Qin Yao5, Jian He1, Yuan Zhou6, Hongbo Cai7 and Yongxiang Zhao1,2,3*
- 1Biological Target Diagnosis & Treatment Center, Guangxi Medical University, Nanning 530021, China
- 2The First Affiliated Hospital, Guangxi Medical University, Nanning 530021, China
- 3Department of Immunology, Guangxi Medical University, Nanning 530021, China
- 4Department of Pathology, Arizona Cancer Center, University of Arizona, Tucson, AZ 85724, USA
- 5Zhongshan Hospital, Xiamen University, Xiamen, Fujian 361004, China
- 6Department of Pharmacology, Hunan Normal University Medical College, Changsha, Hunan 410013, China
- 7Department of Pathology, University of Pittsburgh, 200 Lothrop St, BST S-450, Pittsburgh, PA 15213, USA
*Corresponding Author(s):
Xiaoling Lu, Biological Target Diagnosis & treatment Center, Guangxi Medical University, Nanning 530021, China, Tel: +86 771 535 0964, Fax: +86 771 531 2916
Email:
Yongxiang Zhao, Biological Target Diagnosis & treatment Center, Guangxi Medical University, Nanning 530021, China, Tel: +86 771 535 0964, Fax: +86 771 531 2916
Email:
